ProteinQure is a biotech company specializing in the computational design of novel peptides with broad therapeutic applications. The company leverages advanced computational tools, including molecular simulations and artificial intelligence, to create highly targeted and effective peptide-based therapies. Key features and capabilities include:
-
ProteinStudio™ Platform: An integrated computational platform that uses atomic-level simulations and custom AI models to design de novo peptides.
-
Tissue-Specific Delivery: ProteinQure’s peptides can deliver therapeutic payloads intracellularly via receptor-mediated endocytosis, optimizing efficacy and minimizing side effects.
-
High-Affinity Peptides: The company has developed high-affinity peptides targeting cell surface receptors like SORT1, which can be conjugated to various therapeutic modalities, including cytotoxic agents, oligonucleotides, and radioisotopes.
-
Applications in Oncology and Neurology: ProteinQure is advancing a pipeline of peptide-drug conjugates for applications in solid tumors, neurology, and nephrology.
ProteinQure aims to transform patient care by enabling precise and effective treatments through its innovative computational platform.